Publications

2017

  • Pogorelov, V. M.; Rodriguiz, R. M.; Cheng, J.; Huang, M.; Schmerberg, C. M.; Meltzer, H. Y.; Roth, B. L.; Kozikowski, A. P.; Wetsel, W. C. 5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice. Neuropsychopharmacology  (15 March 2017) | doi:10.1038/npp.2017.52
  • Zhang, G.; Cheng, J.; McCorvy, J. D.; Lorello, P. J.; Caldarone, B. J.; Roth, B. L.; Kozikowski, A. P.* Discovery of N‑Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications. Journal of Medicinal Chemistry, 2017, 60, 6273−6288.

2016

  • Cheng, J.; McCorvy, J. D.; Giguere, P. M.; Zhu, H.; Kenakin, T.; Roth, B. L.; Kozikowski, A. P. (2016). “Design and Discovery of Functionally Selective Serotonin 2C (5-HT2C) Receptor Agonists”. Journal of Medicinal Chemistry, 59(21): 9866−9880.
  • Cheng, J.; Giguere, P. M.; Schmerberg, C. M.; Pogorelov, V. M.; Rodriguiz, R. M.; Huang, X.-P.; Zhu, H.; McCorvy, J. D.; Wetsel, W. C.; Roth, B. L.; Kozikowski, A. P. (2016). “Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models”. Journal of Medicinal Chemistry, 59(2): 578–591.

2015

  • Cheng, J.; Kozikowski, A. P. (2015). “We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders”. ChemMedChem 10(12): 1963–1967.
  • Cheng, J.; Giguere, P. M.; Onajole, O. K.; Lv, W.; Gaisin, A.; Gunosewoyo, H.; Schmerberg, C. M.; Pogorelov, V. M.; Rodriguiz, R. M.; Giulio Vistoli, G.; Wetsel, W. C.; Roth, B. L.; Kozikowski, A. P. (2015). Optimization of 2-Phenylcyclopropyl-methylamines as Selective Serotonin 2C Receptor Agonists and Their Evaluation as Potential Antipsychotic Agents. Journal of Medicinal Chemistry, 58(4): 1992–2002.
  • Cheng, J.; Giguere, P. M.; Lv, W.; Roth, B. L.; Kozikowski, A. P. (2015). Design and Synthesis of (2-(5-Chloro-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)cyclopropyl)-methanamine as a Selective Serotonin 2C Agonist. Tetrahedron Lett, 56(23): 3420–3422.

Before 2015

  • Gao, S.; Cheng, J. J.; Ling, C. Y.; Chu, W. J. and Yang, Y. S. (2014). "A Practical Enantioselective Total Synthesis of (-)-(S)-Stepholidine." Tetrahedron Lett 55(35): 4856-4859.
  • Cheng, J.; Qin, J. H.; Guo, S. H.; Qiu H. D. and Zhong Y. (2014). "Design, Synthesis and Evaluation of Novel HDAC Inhibitors as Potential Antitumor Agents." Bioorganic & Medicinal Chemistry Letters 24(19): 4768-4772.
  • Cheng, J.; Fu, L.; Ling C.; and Yang, Y. (2010). "Total Synthesis of (S)-(-)-Stepholidine Using (S)-Tert-Butanesulfinylimine." Heterocycles 81(11): 2581-2592.
  • Guo, Y.; Zhang, H.; Chen, X. T.; Cai, W. X.; Cheng, J.; Yang, Y.; Jin, G. and Zhen, X. (2009). "Evaluation of the Antipsychotic Affect of Bi-acetylated l-Stepholidine (l-SPD-A), a Novel Dopamine and Serotonin Receptor Dual Ligand." Schizophrenia Research 115(1): 41-49.
  • Cheng, J. J. and Yang, Y. S. (2009). "Enantioselective Total Synthesis of (-)-(S)-Stepholidine." Journal of Organic Chemistry 74(23): 9225-9228.